The Role of Pre-existing Cross-Reactive Central Memory CD4 T-Cells in Vaccination With Previously Unseen Influenza Strains.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2019
Historique:
received: 03 12 2018
accepted: 05 03 2019
entrez: 26 4 2019
pubmed: 26 4 2019
medline: 11 7 2020
Statut: epublish

Résumé

Influenza vaccination is a common approach to prevent seasonal and pandemic influenza. Pre-existing antibodies against close viral strains might impair antibody formation against previously unseen strains-a process called original antigenic sin. The role of this pre-existing cellular immunity in this process is, despite some hints from animal models, not clear. Here, we analyzed cellular and humoral immunity in healthy individuals before and after vaccination with seasonal influenza vaccine. Based on influenza-specific hemagglutination inhibiting (HI) titers, vaccinees were grouped into HI-negative and -positive cohorts followed by in-depth cytometric and TCR repertoire analysis. Both serological groups revealed cross-reactive T-cell memory to the vaccine strains at baseline that gave rise to the majority of vaccine-specific T-cells post vaccination. On the contrary, very limited number of vaccine-specific T-cell clones was recruited from the naive pool. Furthermore, baseline quantity of vaccine-specific central memory helper T-cells and clonotype richness of this population directly correlated with the vaccination efficacy. Our findings suggest that the deliberate recruitment of pre-existing cross-reactive cellular memory might help to improve vaccination outcome.

Identifiants

pubmed: 31019503
doi: 10.3389/fimmu.2019.00593
pmc: PMC6458262
doi:

Substances chimiques

Influenza Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

593

Références

Vaccine. 1999 Jan;17(1):82-94
pubmed: 10078611
Science. 2002 Nov 29;298(5599):1797-800
pubmed: 12459592
Annu Rev Immunol. 2003;21:515-46
pubmed: 12500980
Nat Med. 2003 Jul;9(7):921-7
pubmed: 12808447
N Engl J Med. 2004 Nov 11;351(20):2037-40
pubmed: 15492296
J Exp Med. 2005 Mar 7;201(5):667-70
pubmed: 15753200
Nat Med. 2005 Apr;11(4 Suppl):S54-62
pubmed: 15812491
Nat Med. 2005 Oct;11(10):1118-24
pubmed: 16186818
Nat Immunol. 2006 May;7(5):449-55
pubmed: 16622432
Nat Rev Immunol. 2007 Apr;7(4):267-78
pubmed: 17363960
Nat Rev Microbiol. 2007 Jul;5(7):555-63
pubmed: 17558423
Immunity. 2007 Sep;27(3):384-92
pubmed: 17892847
N Engl J Med. 2007 Oct 4;357(14):1373-81
pubmed: 17914038
J Virol. 2008 Feb;82(3):1350-9
pubmed: 18032492
J Exp Med. 2008 Mar 17;205(3):711-23
pubmed: 18332179
Vaccine. 2008 Mar 25;26(14):1786-93
pubmed: 18336965
Nature. 2008 May 29;453(7195):667-71
pubmed: 18449194
Immunity. 2008 Jun;28(6):847-58
pubmed: 18549802
Vaccine. 2008 Sep 12;26 Suppl 4:D41-4
pubmed: 19230158
Curr Opin Immunol. 2009 Jun;21(3):346-51
pubmed: 19500964
Lancet Infect Dis. 2009 Aug;9(8):493-504
pubmed: 19628174
J Immunol. 2009 Sep 1;183(5):3294-301
pubmed: 19648276
Crit Care. 2009;13(6):235
pubmed: 20085663
Med Microbiol Immunol. 2010 May;199(2):117-21
pubmed: 20162304
J Immunol. 2010 Jun 1;184(11):6320-6
pubmed: 20439913
Emerg Infect Dis. 2010 Jun;16(6):1023-4
pubmed: 20507764
Immunol Rev. 2010 May;235(1):244-66
pubmed: 20536568
Public Health Rep. 2010 Apr;125 Suppl 3:16-26
pubmed: 20568566
Immunol Rev. 2011 Jan;239(1):167-77
pubmed: 21198671
Transplantation. 2011 May 15;91(9):1031-5
pubmed: 21358365
Mol Biol Evol. 2011 Sep;28(9):2443-51
pubmed: 21415025
Science. 2011 Aug 12;333(6044):850-6
pubmed: 21798894
J Virol. 2011 Dec;85(24):13310-21
pubmed: 21976658
Nat Med. 2012 Jan 29;18(2):274-80
pubmed: 22286307
Sci Transl Med. 2012 Apr 4;4(128):128ra42
pubmed: 22491952
Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13751-6
pubmed: 22869731
Int J Pharm Investig. 2011 Apr;1(2):64-74
pubmed: 23071924
J Infect Dis. 2013 Jan 15;207(2):297-305
pubmed: 23148285
Viruses. 2012 Sep;4(9):1438-76
pubmed: 23170167
Immunity. 2013 Feb 21;38(2):373-83
pubmed: 23395677
Proc Natl Acad Sci U S A. 2013 May 28;110(22):8761-2
pubmed: 23686453
J Immunol. 2013 Aug 1;191(3):1001-5
pubmed: 23794632
Am J Transplant. 2013 Nov;13(11):2842-54
pubmed: 24020931
Nat Med. 2013 Oct;19(10):1305-12
pubmed: 24056771
Med Microbiol Immunol. 2014 Feb;203(1):35-45
pubmed: 24057515
Trends Immunol. 2014 Aug;35(8):396-402
pubmed: 25043801
Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):13133-8
pubmed: 25157133
J Infect Dis. 2015 May 1;211(9):1408-17
pubmed: 25378637
Vaccine. 2015 Jan 15;33(4):500-6
pubmed: 25498210
J Virol. 2015 Mar;89(6):3308-17
pubmed: 25589639
Bioinformatics. 2015 Sep 15;31(18):2963-71
pubmed: 25987567
Philos Trans R Soc Lond B Biol Sci. 2015 Sep 5;370(1676):null
pubmed: 26194761
Age (Dordr). 2015 Oct;37(5):92
pubmed: 26324155
Front Immunol. 2016 Jan 25;7:10
pubmed: 26834750
Vaccine. 2016 Jun 3;34(26):2926-2933
pubmed: 27038130
Immunol Cell Biol. 2016 Sep;94(8):729-40
pubmed: 27101922
Cell Host Microbe. 2016 Jun 8;19(6):800-13
pubmed: 27281570
PLoS Pathog. 2016 Aug 18;12(8):e1005806
pubmed: 27537358
Cell Rep. 2016 Oct 11;17(3):627-635
pubmed: 27732840
Cell Rep. 2016 Oct 11;17(3):636-644
pubmed: 27732841
Cell. 2016 Nov 3;167(4):1067-1078.e16
pubmed: 27773482
Immune Netw. 2016 Oct;16(5):261-270
pubmed: 27799871
Front Immunol. 2017 Mar 06;8:238
pubmed: 28321225
J Infect Dis. 2017 Jun 15;215(12):1782-1788
pubmed: 28398521
Sci Immunol. 2017 Feb;2(8):
pubmed: 28620653
Trends Immunol. 2018 Jan;39(1):70-79
pubmed: 28867526
Vaccine. 2018 Mar 14;36(12):1599-1605
pubmed: 29454515
Nature. 1998 Jul 30;394(6692):482-5
pubmed: 9697771
Nat Med. 1998 Aug;4(8):975-8
pubmed: 9701254

Auteurs

Mikalai Nienen (M)

Institute for Medical Immunology, Charité University Medicine Berlin, Berlin, Germany.
Berlin-Brandenburg Center for Regenerative Therapies, Charité University Medicine Berlin, Berlin, Germany.
Labor Berlin-Charité Vivantes GmbH, Berlin, Germany.

Ulrik Stervbo (U)

Center for Translational Medicine, Immunology and Transplantation, Marien Hospital Herne, Ruhr University Bochum, Herne, Germany.

Felix Mölder (F)

Genome Informatics, Institute of Human Genetics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Sviatlana Kaliszczyk (S)

Center for Translational Medicine, Immunology and Transplantation, Marien Hospital Herne, Ruhr University Bochum, Herne, Germany.

Leon Kuchenbecker (L)

Applied Bioinformatics, Tübingen University, Tübingen, Germany.

Ludmila Gayova (L)

Bogomolets National Medical University, Kyiv, Ukraine.

Brunhilde Schweiger (B)

Robert-Koch Institute, Berlin, Germany.

Karsten Jürchott (K)

Berlin-Brandenburg Center for Regenerative Therapies, Charité University Medicine Berlin, Berlin, Germany.

Jochen Hecht (J)

Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
Universitat Pompeu Fabra (UPF), Barcelona, Spain.

Avidan U Neumann (AU)

Institute of Environmental Medicine, German Research Center for Environmental Health, Helmholtz Zentrum München, Augsburg, Germany.

Sven Rahmann (S)

Genome Informatics, Institute of Human Genetics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Timm Westhoff (T)

Department of Internal Medicine, Marien Hospital Herne, Ruhr University Bochum, Herne, Germany.

Petra Reinke (P)

Berlin-Brandenburg Center for Regenerative Therapies, Charité University Medicine Berlin, Berlin, Germany.
Department of Nephrology and Intensive Care, Charité University Medicine Berlin, Berlin, Germany.

Andreas Thiel (A)

Berlin-Brandenburg Center for Regenerative Therapies, Charité University Medicine Berlin, Berlin, Germany.

Nina Babel (N)

Berlin-Brandenburg Center for Regenerative Therapies, Charité University Medicine Berlin, Berlin, Germany.
Center for Translational Medicine, Immunology and Transplantation, Marien Hospital Herne, Ruhr University Bochum, Herne, Germany.
Department of Nephrology and Intensive Care, Charité University Medicine Berlin, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH